What is Seres Therapeutics, Inc.'s Market Cap?

Seres Therapeutics, Inc.'s Market Cap is $55.3M, based on as-reported figures from SEC (XBRL) filings.

What is Seres Therapeutics, Inc.'s Price / Sales?

Seres Therapeutics, Inc.'s Price / Sales is 29.4×, based on as-reported figures from SEC (XBRL) filings.

What is Seres Therapeutics, Inc.'s Revenue (TTM)?

Seres Therapeutics, Inc.'s Revenue (TTM) is $1.9M, based on as-reported figures from SEC (XBRL) filings.

What is Seres Therapeutics, Inc.'s Net Income (TTM)?

Seres Therapeutics, Inc.'s Net Income (TTM) is -$22.5M, based on as-reported figures from SEC (XBRL) filings.

What is Seres Therapeutics, Inc.'s EBITDA?

Seres Therapeutics, Inc.'s EBITDA is -$80.6M, based on as-reported figures from SEC (XBRL) filings.

What is Seres Therapeutics, Inc.'s Diluted EPS (TTM)?

Seres Therapeutics, Inc.'s Diluted EPS (TTM) is -2.26, based on as-reported figures from SEC (XBRL) filings.

What is Seres Therapeutics, Inc.'s EBITDA Margin?

Seres Therapeutics, Inc.'s EBITDA Margin is -4279.6%, based on as-reported figures from SEC (XBRL) filings.

Seres Therapeutics, Inc. (MCRB) Financial Statements

Seres Therapeutics, Inc.

SIC 2834 · PHARMACEUTICAL PREPARATIONS

FIGI BBG0099X6868

XNAS · usd

5.56▲ 0.00 (0.00%)

As of 2026-09-09

Valuation

Market Cap

Enterprise Value—

Trailing P/E—

Price / Sales

EV / Revenue—

EV / EBITDA—

Financial Highlights

Revenue (TTM)

Net Income (TTM)

EBITDA

Diluted EPS (TTM)

EBITDA Margin

Net Debt—

Trading Information

Previous Close5.56

Day's Range5.40 – 5.75

52-Week Range4.32 – 29.98

Volume36.6K

Avg Volume62.7K

Share Statistics

Shares Outstanding

Employees66

ExchangeXNAS

Listed2015-06-26

Share count as of August 3, 2026

ViewDetail

Period

Loading Income Statement…

Key questions about Seres Therapeutics, Inc. (MCRB)

What is Seres Therapeutics, Inc.'s Market Cap?: Seres Therapeutics, Inc.'s Market Cap is $55.3M, based on as-reported figures from SEC (XBRL) filings.
What is Seres Therapeutics, Inc.'s Price / Sales?: Seres Therapeutics, Inc.'s Price / Sales is 29.4×, based on as-reported figures from SEC (XBRL) filings.
What is Seres Therapeutics, Inc.'s Revenue (TTM)?: Seres Therapeutics, Inc.'s Revenue (TTM) is $1.9M, based on as-reported figures from SEC (XBRL) filings.
What is Seres Therapeutics, Inc.'s Net Income (TTM)?: Seres Therapeutics, Inc.'s Net Income (TTM) is -$22.5M, based on as-reported figures from SEC (XBRL) filings.
What is Seres Therapeutics, Inc.'s EBITDA?: Seres Therapeutics, Inc.'s EBITDA is -$80.6M, based on as-reported figures from SEC (XBRL) filings.
What is Seres Therapeutics, Inc.'s Diluted EPS (TTM)?: Seres Therapeutics, Inc.'s Diluted EPS (TTM) is -2.26, based on as-reported figures from SEC (XBRL) filings.
What is Seres Therapeutics, Inc.'s EBITDA Margin?: Seres Therapeutics, Inc.'s EBITDA Margin is -4279.6%, based on as-reported figures from SEC (XBRL) filings.